drugset / Trial / NCT07124078
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
Timeline
- Start
- 2026-05-20
- Primary completion
- 2029-01-31
- Completion
- 2029-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axatilimab | Monoclonal antibody | — | — |
| Subject | Cyclosporine | Peptide | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Subject | Ibrutinib | Small molecule | — | — |
| Subject | Imatinib | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | — | — |
| Subject | Mycophenolate Mofetil | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Sirolimus | Small molecule | — | — |
| Subject | Tacrolimus | Small molecule | — | — |